Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ-synuclein, α-synuclein and double α/γ-synuclein null mutant mice

Journal of Neurochemistry

Volumn 89, Issue 5, 2004, Pages 1126-1136

  Robertson, Darren C ^a   Schmidt, Oliver ^a   Ninkina, Natalia ^a   Jones, Paul A ^a   Sharkey, John ^a   Buchman, Vladimir L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Development; Knockout mice; MPTP; Substantia nigra; Synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; GAMMA SYNUCLEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENE INACTIVATION; HISTOPATHOLOGY; IMMUNOBLOTTING; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANIMALS; BETA-SYNUCLEIN; CELL COMPARTMENTATION; CELL COUNT; CRITICAL PERIOD (PSYCHOLOGY); DRUG RESISTANCE; GAMMA-SYNUCLEIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MPTP POISONING; NERVE TISSUE PROTEINS; NEURONS; SUBSTANTIA NIGRA; SYNUCLEINS;

ANIMALIA;

EID: 2642553802     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02378.x     Document Type: Article

References (91)

1. Abeliovich A., Schmitz Y., Farinas I. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Abercrombie M. (1946) Estimation of nuclear population from microtome sections. Anat. Rec 94, 239-247.
3. Alves Da Costa C., Paitel E., Vincent B. and Checler F. (2002) α-Synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 277, 50980-50984.
4. Arai T., Ueda K., Ikeda K. et al. (1999) Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein. Neurosci. Lett. 259, 83-86.
5. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. and Bonini N. M. (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868.
6. Betarbet R., Sherer T. B., Di Monte D. A. and Greenamyre J. T. (2002) Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol. 12, 499-510.
7. Bonini N. M. (2002) Chaperoning brain degeneration. Proc. Natl Acad. Sci. USA 99, 16407-16411.
8. Buchman V. L., Hunter H. J., Pinon L. G., Thompson J., Privalova E. M., Ninkina N. N. and Davies A. M. (1998) Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J. Neurosci. 18, 9335-9341.
9. Burke R. E. (2003) Post-natal developmental programmed cell death in dopamine neurons. Ann. NY Acad. Sci. 991, 69-79.
10. Cabin D. E., Shimazu K., Murphy D. et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22, 8797-8807.
11. Conway K. A., Harper J. D. and Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
12. Conway K. A., Harper J. D. and Lansbury P. T. Jr (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
13. Cookson M. R. (2003) Pathways to Parkinsonism. Neuron 37, 7-10.
14. da Costa C. A., Masliah E. and Checler F. (2003) β-Synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with α-synuclein and implication for Parkinson's disease. J. Biol. Chem. 278, 37330-37335.
15. Dauer W., Kholodilov N., Vila M. et al. (2002) Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524-14529.
16. Dev K. K., Hofele K., Barbieri S., Buchman V. L. and van der Putten H. (2003) Part II: α-Synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, 14-44.
17. Ding T. T., Lee S. J., Rochet J. C. and Lansbury P. T. Jr (2002) Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209-10217.
18. Dong Z., Ferger B., Feldon J. and Bueler H. (2002) Overexpression of Parkinson's disease-associated α-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTR J. Neurobiol. 53, 1-10.
19. Duda J. E., Shah U., Arnold S. E., Lee V. M. and Trojanowski J. Q. (1999) The expression of α-, β-, and γ-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp. Neurol. 160, 515-522.
20. Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
21. Flowers J. M., Leigh P. N., Davies A. M., Ninkina N. N., Buchman V. L., Vaughan J., Wood N. W. and Powell J. F. (1999) Mutations in the gene encoding human persyn are not associated with amyotrophic lateral sclerosis or familial Parkinson's disease. Neurosci. Lett. 274, 21-24.
22. Galvin J. E., Uryu K., Lee V. M. and Trojanowski J. Q. (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc. Natl Acad. Sci. USA 96, 13450-13455.
23. Galvin J. E., Giasson B., Hurtig H. I., Lee V. M. and Trojanowski J. Q. (2000) Neurodegeneration with brain iron accumulation, type 1 is characterized by α-, β-, and γ-synuclein neuropathology. Am. J. Pathol. 157, 361-368.
24. Gosavi N., Lee H. J., Lee J. S., Patel S. and Lee S. J. (2002) Golgi fragmentation occurs in the cells with pre-fibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277, 48984-48992.
25. Hardy J. (2002) Pathways to primary neurodegenerative disease. Neurologia 17, 399-401.
26. Hashimoto M., Rockenstein E., Mante M., Mallory M. and Masliah E. (2001) β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213-223.
27. Helfand S. L. (2002) Neurobiology: chaperones take flight. Science 295, 809-810.
28. Hsu L. J., Sagara Y., Arroyo A. et al. (2000) α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
29. Irizarry M. C., Growdon W., Gomez-Isla T., Newell K., George J. M., Clayton D. F. and Hyman B. T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334-337.
30. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. and Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
31. Kirik D., Annett L. E., Burger C., Muzyczka N., Mandel R. J. and Bjorklund A. (2003) Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 2884-2889.
32. Kowall N. W., Hantraye P., Brouillet E., Beal M. F., McKee A. C. and Ferrante R. J. (2000) MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211-213.
33. Kruger R., Eberhardt O., Riess O. and Schulz J. B. (2002) Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol Med. 8, 236-240.
34. Kruger R., Kuhn W., Muller T et al. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
35. Kruger R., Schols L., Muller T., Kuhn W., Woitalla D., Przuntek H., Epplen J. T. and Riess O. (2001) Evaluation of the γ-synuclein gene in German Parkinson's disease patients. Neurosci. Lett. 310, 191-193.
36. Kuhn K., Wellen J., Link N., Maskri L., Lubbert H. and Stichel C. C. (2003) The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17, 1-12.
37. Lakso M., Vartiainen S., Moilanen A. M., Sirvio J., Thomas J. H., Nass R., Blakely R. D. and Wong G. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J. Neurochem. 86, 165-172.
38. Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. and Lansbury P. T. Jr (2002) α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102.
39. Lavedan C., Buchholtz S., Auburger G. et al. (1998b) Absence of mutation in the β- and γ-synuclein genes in familial autosomal dominant Parkinson's disease. DNA Res. 5, 401-402.
40. Lavedan C., Leroy E., Dehejia A., Buchholtz S., Dutra A., Nussbaum R. L. and Polymeropoulos M. H. (1998a) Identification, localization and characterization of the human γ-synuclein gene. Hum. Genet. 103, 106-112.
41. Lee S. J. (2003) α-Synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? Antioxid. Redox Signal 5, 337-348.
42. Lee M., Hyun D., Halliwell B. and Jenner P. (2001) Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009.
43. Lehmensiek V., Tan E. M., Schwarz J. and Storch A. (2002) Expression of mutant α-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Neuroreport 13, 1279-1283.
44. Lincoln S., Crook R., Chartier-Harlin M. C. et al. (1999a) No pathogenic mutations in the β-synuclein gene in Parkinson's disease. Neurosci. Lett. 269, 107-109.
45. Lincoln S., Gwinn-Hardy K., Goudreau J. et al. (1999b) No pathogenic mutations in the persyn gene in Parkinson's disease. Neurosci. Lett. 259, 65-66.
46. Lippa C. F., Schmidt M. L., Lee V. M. and Trojanowski J. Q. (1999) Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45, 353-357.
47. Lo Bianco C., Ridet J. L., Schneider B. L., Deglon N. and Aebischer P. (2002) α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813-10818.
48. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H. K. and Brundin P. (2002) Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894.
49. Lotharius J. and Brundin P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci. 3, 932-942.
50. Mattson M. P., Duan W., Chan S. L., Cheng A., Haughey N., Gary D. S., Guo Z., Lee J. and Furukawa K. (2002) Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. Neurobiol. Aging 23, 695-705.
51. Meredith G. E., Totterdell S., Petroske E., Santa Cruz K., Callison R. C. Jr and Lau Y. S. (2002) Lysosomal malfunction accompanies α-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956, 156-165.
52. Mezey E., Dehejia A. M., Harta G., Tresser N., Suchy S. F., Nussbaum R. L., Brownstein M. J. and Polymeropoulos M. H. (1998) α-Synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol. Psychiatry 3, 493-499.
53. Mori F., Hayashi S., Yamagishi S., Yoshimoto M., Yagihashi S., Takahashi H. and Wakabayashi K. (2002) Pick's disease: α- and β -synuclein-immunoreactive Pick bodies in the dentate gyrus. Acta Neuropathol. 104, 455-461.
54. Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
55. Ninkina N., Papachroni K., Robertson D. C. et al. (2003) Neurons expressing the highest levels of γ-synuclein are unaffected by targeted inactivation of the gene. Mol. Cell Biol. 23, 8233-8245.
56. Ninkina N. N., Privalova E. M., Pinon L. G., Davies A. M. and Buchman V. L. (1999) Developmentally regulated expression of persyn, a member of the synuclein family, in skin. Exp. Cell Res. 246, 308-311.
57. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J. and Wolozin B. (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791.
58. Park J. Y. and Lansbury P. T. Jr (2003) β-Synuclein inhibits formation of α-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 42, 3696-3700.
59. Petrucelli L., O'Farrell C., Lockhart P. J. et al. (2002) Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019.
60. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
61. Przedborski S., Chen Q., Vila M., Giasson B. I., Djaldatti R., Vukosavic S., Souza J. M., Jackson-Lewis V., Lee V. M. and Ischiropoulos H. (2001b) Oxidative post-translational modifications of α-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76, 637-640.
62. Przedborski S., Jackson-Lewis V., Naini A. B., Jakowec M., Petzinger G., Miller R. and Akram M. (2001a) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274.
63. Rathke-Hartlieb S., Kahle P. J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C. and Schulz J. B. (2001) Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J. Neurochem. 77, 1181-1184.
64. Richfield E. K., Thiruchelvam M. J., Cory-Slechta D. A., Wuertzer C., Gainetdinov R. R., Caron M. G., Di Monte D. A. and Federoff H. J. (2002) Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol. 175, 35-48.
65. Saha A. R., Ninkina N. N., Hanger D. P., Anderton B. H., Davies A. M. and Buchman V. L. (2000) Induction of neuronal death by α-synuclein. Eur. J. Neurosci. 12, 3073-3077.
66. Schluter O. M., Fornai F., Alessandri M. G., Takamori S., Geppert M., Jahn R. and Sudhof T. C. (2003) Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 118, 985-1002.
67. Schwartz L. M., Nambu J. R. and Wang Z. (2002) Parkinsonism proteolysis and proteasomes. Cell Death Differ 9, 479-482.
68. Serpell L. C., Berriman J., Jakes R., Goedert M. and Crowther R. A. (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl Acad. Sci. USA 97, 4897-4902.
69. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840.
70. Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L. and Goedert M. (1998b) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208.
71. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998a) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473.
72. Stefanis L., Larsen K. E., Rideout H. J., Sulzer D. and Greene L. A. (2001) Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549-9560.
73. Takeda A., Hashimoto M., Mallory M., Sundsumo M., Hansen L. and Masliah E. (2000) C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol. 99, 296-304.
74. Tatton N. A. and Kish S. J. (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77, 1037-1048.
75. Uversky V. N. and Fink A. L. (2002) Amino acid determinants of α-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522, 9-13.
76. Uversky V. N., Li J., Souillac P., Millett I. S., Doniach S., Jakes R., Goedert M. and Fink A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synucleins. J. Biol. Chem. 277, 11970-11978.
77. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. and Przedborski S. (2000) α-Synuclein upregulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721-729.
78. Volles M. J. and Lansbury P. T. Jr (2002) Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602.
79. Volles M. J. and Lansbury P. T. Jr (2003) Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871-7878.
80. Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C. and Lansbury P. T. Jr (2001) Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
81. Wakabayashi K., Yoshimoto M., Tsuji S. and Takahashi H. (1998) α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180-182.
82. Welch K. and Yuan J. (2002) Releasing the nerve cell killers. Nat. Med. 8, 564-565.
83. 2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants. Neurosci. Lett. 342, 124-128.
84. Windisch M., Hutter-Paier B., Rockenstein E., Hashimoto M., Mallory M. and Masliah E. (2002) Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory β-synuclein-derived peptides. J. Mol. Neurosci. 19, 63-69.
85. Wolozin B. and Golts N. (2002) Iron and Parkinson's disease. Neuroscientist 8, 22-32.
86. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M. and Biere A. L. (1999) α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
87. Xu J., Kao S. Y., Lee F. J., Song W., Jin L. W. and Yankner B. A. (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. 8, 600-606.
88. Zhou W., Hurlbert M. S., Schaack J., Prasad K. N. and Freed C. R. (2000) Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 33-43.
89. Zhou W., Schaack J., Zawada W. M. and Freed C. R. (2002) Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926, 42-50.
90. Zhu M., Li J. and Fink A. L. (2003) The association of α-synuclein with membranes affects bilayer structure, stability and fibril formation. J. Biol. Chem. 278, 40186-40197.
91. Zourlidou A., Payne Smith M. D. and Latchman D. S. (2003) Modulation of cell death by α-synuclein is stimulus-dependent in mammalian cells. Neurosci. Lett. 340, 234-238.